SS Innovations Secures Regulatory Approval in Indonesia for Flagship Surgical Robotic System

Leading developer of innovative surgical robotic technologies, SS Innovations International (OTC: SSII) has secured regulatory approval from the Indonesian Ministry of Health for clinical use for the use of its flagship surgical robotic system, the SSi Mantra, in the Republic of Indonesia. Indonesia has a population of approximately 280 million and is the world’s fourth most populous country.

Dr. Sudhir Srivastava, SS Innovation’s Chairman and CEO, said, “With the entry of the SSi Mantra to the Indonesian market, we believe that we can be instrumental in increasing access to and decreasing costs of robotic surgery options. We look forward to broadening surgical horizons for Indonesians and continuing to expand our innovative surgical services and options across the globe.”

Robotic surgery has been slow to be adopted in Indonesia, where the nation’s Bunda Hospital in Jakarta acquired its first robotic surgical system in 2012 and has only completed about 700 surgeries to date.

The SSi Mantra is one of the only systems in the world designed to be cost-effective with broad-spectrum surgical applications. SS Innovations is working to secure regulatory approval in the United States and the European Union.

About SS Innovations International, Inc.

SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at or LinkedIn for updates.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

SS Innovations Secures Regulatory Approval in Indonesia for Flagship Surgical Robotic System

Catie Corcoran

Biotech Editor